Teva Attempts to Launch Generic Version of Gilead Drug

27 January 2010 (Last Updated January 27th, 2010 18:30)

Teva Pharmaceuticals has submitted an Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration requesting permission to manufacture and market a generic version of Gilead Sciences' Viread drug. In the letter Teva alleges that three patents associated with Viread (t

Teva Pharmaceuticals has submitted an Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration requesting permission to manufacture and market a generic version of Gilead Sciences' Viread drug.

In the letter Teva alleges that three patents associated with Viread (tenofovir disoproxil fumarate) owned by Gilead Sciences are invalid, unenforceable and/or will not be infringed by Teva's manufacture or sale of the product.

Gilead said it is reviewing the ANDA and has 45 days from receipt of the letter to begin a patent infringement lawsuit against Teva.